BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

640 related articles for article (PubMed ID: 17982462)

  • 21. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
    Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
    Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts.
    Venkateswaran V; Haddad AQ; Fleshner NE; Fan R; Sugar LM; Nam R; Klotz LH; Pollak M
    J Natl Cancer Inst; 2007 Dec; 99(23):1793-800. PubMed ID: 18042933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.
    Medicherla S; Li L; Ma JY; Kapoun AM; Gaspar NJ; Liu YW; Mangadu R; O'Young G; Protter AA; Schreiner GF; Wong DH; Higgins LS
    Anticancer Res; 2007; 27(6B):4149-57. PubMed ID: 18229422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epitope mapping of the transforming growth factor-beta superfamily protein, macrophage inhibitory cytokine-1 (MIC-1): identification of at least five distinct epitope specificities.
    Fairlie WD; Russell PK; Wu WM; Moore AG; Zhang HP; Brown PK; Bauskin AR; Breit SN
    Biochemistry; 2001 Jan; 40(1):65-73. PubMed ID: 11141057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. c-Ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-beta signaling in diffuse-type gastric carcinoma.
    Kiyono K; Suzuki HI; Morishita Y; Komuro A; Iwata C; Yashiro M; Hirakawa K; Kano MR; Miyazono K
    Cancer Sci; 2009 Oct; 100(10):1809-16. PubMed ID: 19594546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.
    Malinowska K; Neuwirt H; Cavarretta IT; Bektic J; Steiner H; Dietrich H; Moser PL; Fuchs D; Hobisch A; Culig Z
    Endocr Relat Cancer; 2009 Mar; 16(1):155-69. PubMed ID: 19011039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improving food intake in anorectic cancer patients.
    Laviano A; Meguid MM; Rossi-Fanelli F
    Curr Opin Clin Nutr Metab Care; 2003 Jul; 6(4):421-6. PubMed ID: 12806216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
    Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
    Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of a metalloporphyrin antioxidant (MnTE-2-PyP) on the response of a mouse prostate cancer model to radiation.
    Makinde AY; Luo-Owen X; Rizvi A; Crapo JD; Pearlstein RD; Slater JM; Gridley DS
    Anticancer Res; 2009 Jan; 29(1):107-18. PubMed ID: 19331139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological characterization of a small molecule inhibitor of c-Jun kinase.
    Cho H; Black SC; Looper D; Shi M; Kelly-Sullivan D; Timofeevski S; Siegel K; Yu XH; McDonnell SR; Chen P; Yie J; Ogilvie KM; Fraser J; Briscoe CP
    Am J Physiol Endocrinol Metab; 2008 Nov; 295(5):E1142-51. PubMed ID: 18728225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transforming growth factor beta derived from bone matrix promotes cell proliferation of prostate cancer and osteoclast activation-associated osteolysis in the bone microenvironment.
    Sato S; Futakuchi M; Ogawa K; Asamoto M; Nakao K; Asai K; Shirai T
    Cancer Sci; 2008 Feb; 99(2):316-23. PubMed ID: 18271931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytosine deaminase-uracil phosphoribosyltransferase and interleukin (IL)-12 and IL-18: a multimodal anticancer interface marked by specific modulation in serum cytokines.
    Khatri A; Husaini Y; Ow K; Chapman J; Russell PJ
    Clin Cancer Res; 2009 Apr; 15(7):2323-34. PubMed ID: 19318483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
    Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
    Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anorexia/cachexia of chronic diseases: a role for the TGF-β family cytokine MIC-1/GDF15.
    Tsai VW; Husaini Y; Manandhar R; Lee-Ng KK; Zhang HP; Harriott K; Jiang L; Lin S; Sainsbury A; Brown DA; Breit SN
    J Cachexia Sarcopenia Muscle; 2012 Dec; 3(4):239-43. PubMed ID: 22936174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism.
    Van Aarsen LA; Leone DR; Ho S; Dolinski BM; McCoon PE; LePage DJ; Kelly R; Heaney G; Rayhorn P; Reid C; Simon KJ; Horan GS; Tao N; Gardner HA; Skelly MM; Gown AM; Thomas GJ; Weinreb PH; Fawell SE; Violette SM
    Cancer Res; 2008 Jan; 68(2):561-70. PubMed ID: 18199553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anorexia-cachexia syndrome in hepatoma tumour-bearing rats requires the area postrema but not vagal afferents and is paralleled by increased MIC-1/GDF15.
    Borner T; Arnold M; Ruud J; Breit SN; Langhans W; Lutz TA; Blomqvist A; Riediger T
    J Cachexia Sarcopenia Muscle; 2017 Jun; 8(3):417-427. PubMed ID: 28025863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective inhibition of fatty acid synthase for lung cancer treatment.
    Orita H; Coulter J; Lemmon C; Tully E; Vadlamudi A; Medghalchi SM; Kuhajda FP; Gabrielson E
    Clin Cancer Res; 2007 Dec; 13(23):7139-45. PubMed ID: 18056164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of transforming growth factor beta on human neuroendocrine tumor BON cell proliferation and differentiation is mediated through somatostatin signaling.
    Leu FP; Nandi M; Niu C
    Mol Cancer Res; 2008 Jun; 6(6):1029-42. PubMed ID: 18567806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity.
    Hua D; Liu MY; Cheng ZD; Qin XJ; Zhang HM; Chen Y; Qin GJ; Liang G; Li JN; Han XF; Liu DX
    Mol Immunol; 2009 Sep; 46(15):2876-84. PubMed ID: 19643479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity.
    Finger EC; Turley RS; Dong M; How T; Fields TA; Blobe GC
    Carcinogenesis; 2008 Mar; 29(3):528-35. PubMed ID: 18174241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.